Insider Transactions in Q1 2025 at Organogenesis Holdings Inc. (ORGO)
Insider Transaction List (Q1 2025)
Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
---|---|---|---|---|---|
Mar 09
2025
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
271
-0.07%
|
$1,355
$5.16 P/Share
|
Mar 04
2025
|
Michael Joseph Driscoll Director |
SELL
Open market or private sale
|
Direct |
25,000
-13.03%
|
$125,000
$5.1 P/Share
|
Mar 01
2025
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
667
-0.35%
|
$4,002
$6.21 P/Share
|
Feb 19
2025
|
Robert Cavorsi Vice President, Strategy |
BUY
Grant, award, or other acquisition
|
Direct |
61,705
+24.47%
|
-
|
Feb 19
2025
|
David Francisco Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
165,156
+22.8%
|
-
|
Feb 19
2025
|
Lori Freedman Chief Admin. and Legal Officer |
BUY
Grant, award, or other acquisition
|
Direct |
162,047
+21.43%
|
-
|
Feb 19
2025
|
Brian Grow Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
183,067
+21.45%
|
-
|
Feb 19
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
BUY
Grant, award, or other acquisition
|
Direct |
42,493
+17.77%
|
-
|
Feb 19
2025
|
Patrick Bilbo Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
184,136
+16.25%
|
-
|
Feb 19
2025
|
Arthur S Leibowitz Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+17.29%
|
-
|
Feb 19
2025
|
Garrett Lustig Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+39.19%
|
-
|
Feb 19
2025
|
Gilberto Quintero Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.67%
|
-
|
Feb 19
2025
|
Jon L Giacomin Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.5%
|
-
|
Feb 19
2025
|
Gary S. Gillheeney President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
708,215
+16.77%
|
-
|
Feb 19
2025
|
Michele Ilene Korfin Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.67%
|
-
|
Feb 19
2025
|
Michael Joseph Driscoll Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.53%
|
-
|
Feb 19
2025
|
Prathyusha Duraibabu Director |
BUY
Grant, award, or other acquisition
|
Direct |
49,575
+20.01%
|
-
|
Feb 16
2025
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,123
-0.22%
|
$18,369
$3.7 P/Share
|
Feb 16
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
719
-0.46%
|
$2,157
$3.7 P/Share
|
Feb 16
2025
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
804
-0.2%
|
$2,412
$3.7 P/Share
|
Feb 16
2025
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
646
-0.15%
|
$1,938
$3.7 P/Share
|
Feb 16
2025
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
790
-0.1%
|
$2,370
$3.7 P/Share
|
Feb 16
2025
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
656
-0.13%
|
$1,968
$3.7 P/Share
|
Feb 15
2025
|
Gary S. Gillheeney President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
225,963
-2.54%
|
$677,889
$3.7 P/Share
|
Feb 15
2025
|
Antonio S. Montecalvo Vice President, Health Policy |
SELL
Payment of exercise price or tax liability
|
Direct |
13,362
-2.7%
|
$40,086
$3.7 P/Share
|
Feb 15
2025
|
Robert Cavorsi Vice President, Strategy |
SELL
Payment of exercise price or tax liability
|
Direct |
11,008
-4.02%
|
$33,024
$3.7 P/Share
|
Feb 15
2025
|
David Francisco Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
34,253
-2.72%
|
$102,759
$3.7 P/Share
|
Feb 15
2025
|
Lori Freedman Chief Admin. and Legal Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
36,478
-2.65%
|
$109,434
$3.7 P/Share
|
Feb 15
2025
|
Patrick Bilbo Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
43,366
-1.81%
|
$130,098
$3.7 P/Share
|
Feb 15
2025
|
Brian Grow Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
32,730
-2.13%
|
$98,190
$3.7 P/Share
|
Jan 09
2025
|
Alan A. Ades Director |
BUY
Bona fide gift
|
Direct |
12,803,890
+11.14%
|
-
|
Jan 09
2025
|
Alan A. Ades Director |
BUY
Bona fide gift
|
Indirect |
12,803,890
+11.14%
|
-
|
Jan 09
2025
|
Alan A. Ades Director |
SELL
Bona fide gift
|
Direct |
12,803,890
-11.14%
|
-
|